Sclerotherapy of testicular hydroceles with 3% aqueous phenol.

Abstract

With the evolution of minimally invasive approaches in medicine, phenol has regained its popularity for the sclerotherapy of testicular hydroceles. Together with reported efficiency and safety of 2.5% phenol in the literature, the recently proved safety of 3% phenol in esophageal variceal sclerotherapy has led us to perform a prospective study to lessen the number of sessions. Sclerotherapy with 3% aqueous phenol was applied on an ambulatory basis to 23 patients with 31 hydroceles, who were over 40 years old and who had no fertility problems. The over-all cure rate was 96% with an average follow-up of 3 years, and 58% of the hydroceles required only one session of treatment. The average number of treatment sessions was 2.2 (range; 1-7). One patient with a history of herniorraphy 10 years earlier, was treated surgically following failure of seven sclerotherapy sessions. Phenol, a sclerosant superior to other conventional agents including tetracyclines, requires neither anesthetics nor prophylactic antibiotics. Our findings indicate that sclerotherapy with 3% phenol is an effective, economical and safe form of therapy for patients with hydrocele.

• Authors: E Ozdemir
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 42 Issue 6 Pg. 427-32 (Jun 1996) ISSN: 0018-1994 [Print] Japan
• PMID: 8741297 (Publication Type: Journal Article)

Chemical References

• Phenols
• Sclerosing Solutions

Topics

• Adult
• Aged
• Humans
• Male
• Middle Aged
• Phenols (administration & dosage)
• Prospective Studies
• Sclerosing Solutions (administration & dosage)
• Sclerotherapy (methods)
• Testicular Diseases (therapy)
• Testicular Hydrocele (therapy)
• Treatment Outcome